Imaging the influence and interaction of genes and stimulant medication on attention in Attention Deficit Hyperactivity Disorder (ADHD).

Phase 3

Completed

• Conditions: Attention Deficit Hyperactivity Disorder (ADHD); Mental Health - Other mental health disorders

• Registration Number: ACTRN12610000652077
• Lead Sponsor: Dr. Tim Silk

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2010-08-11
• Study Completion: 2012-10-03
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

ADHD (combined type)
Healthy, matched control adolescents (Placebo only)
right handed

Exclusion Criteria

Weight under 35kg
Full scale Intelligence Quotient (FSIQ) >70
Conners Parent Rating Scale (CPRS) >65 for ADHD, <60 for controls
gluten intolerance (due to presence in placebo)
wearing dental braces
no reading disabilities,
no comorbidities, of major depression, Autism Spectrum Disorders, or psychosis

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes in Blood Oxygenation Level Dependent (BOLD) response, measured by functional Magnetic Resonance Imaging (fMRI), as a function of medication.[ Two MRI scanning sessions conducted two weeks apart. A single dose of either methylphenidate or placebo will be taken 90 minutes prior to scanning session.];Changes in Blood Oxygenation Level Dependent (BOLD) response, measured by functional Magnetic Resonance Imaging (fMRI), as a function of DAT1 genotype.[ Two MRI scanning sessions conducted two weeks apart. A single dose of either methylphenidate or placebo will be taken 90 minutes prior to scanning session.]

Secondary Outcome Measures

Name	Time	Method
il[ Nil]